share_log

“减肥神药”再迎利好!礼来(LLY.US)tirzepatide在治疗睡眠障碍后期试验取得积极结果

“Weight loss elixir” welcomes benefits again! LY.US (LLY.US) tirzepatide achieved positive results in late-stage trials to treat sleep disorders

Zhitong Finance ·  Apr 17 08:50

Lily.US (LLY.US) announced on Wednesday that its weight loss therapy tirzepatide has achieved major goals in two phase 3 trials targeting patients with obesity and obstructive sleep apnea (OSA).

The Zhitong Finance App learned that LLY.US (LLY.US) announced on Wednesday that its weight loss therapy tirzepatide has achieved major goals in two phase 3 trials for patients with obesity and obstructive sleep apnea (OSA).

The pharmaceutical giant said that compared to placebo, tirzepatide (trade name Zepbound) significantly reduced the apnea hypoventilation index (AHI), which was the primary end point of the trial.

Eli Lilly's SURMOUNT-OSA project involved 469 adults with moderate to severe OSA and obesity in multiple countries, and the company said the project also reached a critical secondary endpoint based on percentage changes in AHI.

In two trials, injecting the drug reduced the patient's body weight by nearly 20% at 52 weeks. Of these, 70% of the test subjects were men. Compared with women, they responded less well to enterostimulating insulin treatments such as tirzepatide.

Eli Lilly said that most adverse events are related to the gastrointestinal tract, and the severity is generally mild to moderate.

Starting in mid-2024, the company plans to submit SURMOUNT-OSA data to peer-reviewed journals and share the results with regulators, including the US FDA.

Ventilator equipment manufacturer ResMed (RMD.US), Inspire Medical Systems (INSP.US), Philips (PHG.US), and sleep apnea drug developer Jazz Pharmaceuticals (JAZZ.US) may be affected.

According to information, with the GLP-1 agonist approved by the FDA, Eli Lilly and Novo Nordisk (NVO.US) dominates the novel diet drug market.

As of press time, Eli Lilly was up 2.58% to $766.00 in the premarket.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment